BioMarin Pharmaceuticals BMRN Business Segments — G&A expenses

Similar metrics at other companies

GILDReportable Segment — General and administrative expenses

$553M+9.5%

AMGNReportable Segment — G&A

$468M-24.6%

ADBEReportable Segment — General and Administrative, Significant Segment Expense

$364M+15.6%

FTNTReportable Segment — G&A

$56.2M-2.8%

MANEReportable Segment — General and administrative, excluding personnel expenses

$4.61M+339%

GHReportable Segment — General and administrative expense

$37.04M+21.2%

Questions, answered.

What is BioMarin Pharmaceuticals's business segments — G&A expenses?

BioMarin Pharmaceuticals (BMRN) reported business segments — G&A expenses of $133.36M in Q1 2026.

How has BioMarin Pharmaceuticals's business segments — G&A expenses changed year-over-year?

BioMarin Pharmaceuticals's business segments — G&A expenses increased by 28.7% year-over-year, from $103.59M to $133.36M.

What is the long-term trend for BioMarin Pharmaceuticals's business segments — G&A expenses?

Over 3 years (2022 to 2025), BioMarin Pharmaceuticals's business segments — G&A expenses has grown at a 18.7% compound annual growth rate (CAGR), from $372.89M to $622.86M.

What does business segments — G&A expenses mean?

The overhead and administrative costs required to support the segment's daily operations.

How do you interpret business segments — G&A expenses?

An increase relative to revenue may suggest rising administrative overhead, whereas a decrease indicates improved operational leverage.

How does business segments — G&A expenses compare across companies?

Comparable to general and administrative expense allocations in segment reporting for large pharmaceutical companies.